ADC Therapeutics Email Format

Biotechnology Research
51-200 employees
Lausanne, Vaud, Switzerland

ADC Therapeutics is a commercial-stage biotechnology company pioneering antibody drug conjugates for cancer treatment, with an FDA-approved product and global operations.

Find contacts at ADC Therapeutics

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@adctherapeutics.com

Company Overview

Industry
Biotechnology Research
Founded
2011
Headquarters
Lausanne, Vaud, Switzerland
Revenue
$100M-$250M
FUNDING Stage
Public
Key Executives
Ameet Mallik (Chief Executive Officer), Jose "Pepe" Carmona (Chief Financial Officer), David Ege, PhD (Chief Technical Officer)

Tech Stack

Salesforce

CRM

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of ADC Therapeutics?

ADC Therapeutics uses the first.last format on adctherapeutics.com, so Jane Smith would be jane.smith@adctherapeutics.com.

What is ADC Therapeutics' approved commercial product and what cancer does it treat?

ADC Therapeutics markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed antibody drug conjugate approved by the FDA for adults with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma.

Who is the CEO of ADC Therapeutics?

Ameet Mallik serves as President and CEO of ADC Therapeutics. Before joining the company in 2022, he spent 16 years at Novartis, most recently as Executive Vice President and Head of U.S. Oncology.

How many clinical trials does ADC Therapeutics have running for ZYNLONTA in B-cell lymphoma?

ADC Therapeutics has multiple active ZYNLONTA trials including LOTIS-5, a Phase 3 confirmatory study in relapsed or refractory DLBCL, and LOTIS-7, a Phase 1b combination study in B-cell non-Hodgkin lymphoma, with topline data expected in 2026.

Where can I find and verify contact details for ADC Therapeutics employees?

ADC Therapeutics is headquartered in Lausanne, Switzerland and has 273 employees. Tools like Clay can help you verify individual employee email addresses and build accurate outreach lists using the confirmed first.last@adctherapeutics.com format.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles